Successful treatment of mitomycin C-associated hemolytic uremic syndrome by plasmapheresis.

Therapeutic attempts have generally failed to reverse the rapid progression of renal failure after mitomycin C (MMC)-induced hemolytic uremic syndrome (HUS). A patient who developed HUS after MMC and who showed pathologic changes in the kidney consistent with thrombotic microangiopathy is reported. Treatment with plasmapheresis was followed by a favorable outcome and significant recovery of renal function. Accordingly, this therapeutic modality should be considered for patients with MMC-induced HUS.